Effect of halofuginone on the development of tight skin (TSK) syndrome

Tracy L. McGaha, Takao Kodera, Robert Phelps, Harry Spiera, Mark Pines, Constantin Bona

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The endpoint of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin scleroris when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.

Original languageEnglish (US)
Pages (from-to)277-282
Number of pages6
JournalAutoimmunity
Volume35
Issue number4
DOIs
StatePublished - Aug 29 2002

Fingerprint

Skin
Fibrosis
Collagen
Therapeutics
Collagen Type I
Connective Tissue
Autoantibodies
Hyperplasia
Fibroblasts
Cell Count
halofuginone
Morbidity
Antigens
Mortality
Pharmaceutical Preparations
Genes

Keywords

  • Collagen
  • Fibrosis
  • Halofuginone
  • Scleroderma
  • Tight skin mouse

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

McGaha, T. L., Kodera, T., Phelps, R., Spiera, H., Pines, M., & Bona, C. (2002). Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity, 35(4), 277-282. https://doi.org/10.1080/0891693021000001235

Effect of halofuginone on the development of tight skin (TSK) syndrome. / McGaha, Tracy L.; Kodera, Takao; Phelps, Robert; Spiera, Harry; Pines, Mark; Bona, Constantin.

In: Autoimmunity, Vol. 35, No. 4, 29.08.2002, p. 277-282.

Research output: Contribution to journalArticle

McGaha, TL, Kodera, T, Phelps, R, Spiera, H, Pines, M & Bona, C 2002, 'Effect of halofuginone on the development of tight skin (TSK) syndrome', Autoimmunity, vol. 35, no. 4, pp. 277-282. https://doi.org/10.1080/0891693021000001235
McGaha TL, Kodera T, Phelps R, Spiera H, Pines M, Bona C. Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity. 2002 Aug 29;35(4):277-282. https://doi.org/10.1080/0891693021000001235
McGaha, Tracy L. ; Kodera, Takao ; Phelps, Robert ; Spiera, Harry ; Pines, Mark ; Bona, Constantin. / Effect of halofuginone on the development of tight skin (TSK) syndrome. In: Autoimmunity. 2002 ; Vol. 35, No. 4. pp. 277-282.
@article{6a6e8fb93f624121ae13324e55608fd6,
title = "Effect of halofuginone on the development of tight skin (TSK) syndrome",
abstract = "The endpoint of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin scleroris when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.",
keywords = "Collagen, Fibrosis, Halofuginone, Scleroderma, Tight skin mouse",
author = "McGaha, {Tracy L.} and Takao Kodera and Robert Phelps and Harry Spiera and Mark Pines and Constantin Bona",
year = "2002",
month = "8",
day = "29",
doi = "10.1080/0891693021000001235",
language = "English (US)",
volume = "35",
pages = "277--282",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Effect of halofuginone on the development of tight skin (TSK) syndrome

AU - McGaha, Tracy L.

AU - Kodera, Takao

AU - Phelps, Robert

AU - Spiera, Harry

AU - Pines, Mark

AU - Bona, Constantin

PY - 2002/8/29

Y1 - 2002/8/29

N2 - The endpoint of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin scleroris when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.

AB - The endpoint of pathogenic events in scleroderma is fibrosis of the skin and internal organs. Fibrosis in scleroderma results from the over synthesis and deposition of collagen in the connective tissue. The morbidity and mortality of the scleroderm is very high and presently there is no specific treatment. Halofuginone is a drug with great potential for the treatment of scleroderma since it inhibits the synthesis of collagen type I by fibroblasts. We have studied the in vivo effect of halofuginone in tight skin (TSK) mice that spontaneously develop a scleroderma-like disease due to a genetic defect. Our results demonstrate that halofuginone prevented the occurrence of skin scleroris when administered to newborn mice and reduced cutaneous hyperplasia when administered in adult TSK mice. These effects correlated with a decreased number of cells synthesizing collagen gene transcripts and a reduction in the level of autoantibodies specific for human target antigens. These results indicate that halofuginone may have use as a therapeutic in the treatment of fibrotic disease.

KW - Collagen

KW - Fibrosis

KW - Halofuginone

KW - Scleroderma

KW - Tight skin mouse

UR - http://www.scopus.com/inward/record.url?scp=0035995041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035995041&partnerID=8YFLogxK

U2 - 10.1080/0891693021000001235

DO - 10.1080/0891693021000001235

M3 - Article

C2 - 12482197

AN - SCOPUS:0035995041

VL - 35

SP - 277

EP - 282

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 4

ER -